The Foundation for Sarcoidosis Research (FSR) brought together more than 40 leading clinicians and researchers from around the world for an in-person meeting of the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) and the FSR Sarcoidosis Biomarker Summit. Together, these two gatherings marked a major step forward in international collaboration…
Higher, daily exposure to microorganisms during childhood is significantly associated with an increased chance of developing sarcoidosis in adulthood, according to a study in Japan. Among the risk factors identified are attending nursing school and using well water. A smoking history during adulthood was also significantly linked to a…
Atyr Pharma and the U.S. Food and Drug Administration (FDA) have aligned on the specific main outcome analysis of the ongoing Phase 3 clinical trial that’s testing the company’s investigational therapy efzofitimod in people with pulmonary sarcoidosis. Based on FDA feedback during a recent type C meeting,…
A global Phase 3 clinical trial evaluating efzofitimod, Atyr Pharma’s investigational therapy, in people with pulmonary sarcoidosis will continue as planned following a third pre-planned interim safety review. An independent data safety and monitoring board (DSMB) examined available safety and tolerability data from all 268 participants enrolled in…
Damage to and the loss of bile ducts, which are the tubes that carry the digestive fluid bile from the liver to the intestines, may be a sign of progressive liver disease among people with sarcoidosis, a study found. Such abnormalities appeared independent of inflammation related to granulomas, the…
A woman in her 50s in Florida who presented with recurrent ministrokes was eventually diagnosed with sarcoidosis only affecting the heart, called isolated cardiac sarcoidosis, a case study reports. “This case highlights the need to consider [cardiac sarcoidosis] as a potential cause of [stroke-like] events in patients with few…
A new modeling approach that incorporates standard tests and clinical signs can identify people who have sarcoidosis-associated uveitis (SAU), or inflammation of the eye, a new study shows. Based on this analysis, data showed a combination of eye tests could distinguish SAU from non-SAU patients with a high degree…
An immunosuppressive medication that’s used to prevent organ rejection after transplantation successfully treated cutaneous sarcoidosis, a type of sarcoidosis of the skin, in most patients in a small clinical trial. Sirolimus, which suppresses a signaling pathway called mTOR, reduced or eliminated skin granulomas and its benefits persisted for…
Bone fractures, particularly those of the spine, are a common complication among people with sarcoidosis, according to a study that assessed nearly 400 patients. Data showed that sarcoidosis-related lung involvement and reduced lung function were risk factors for major bone fractures. Chest X-rays examining lung involvement, as well as…
Blood levels of the angiotensin-converting enzyme (ACE) — a common sarcoidosis biomarker — were able to distinguish between newly diagnosed sarcoidosis patients with single versus multiple organ involvement, a study shows. Also, higher blood levels of interleukin-2 receptor (IL-2R), an inflammatory marker, were linked with multiple organ involvement. ACE…
Get regular updates to your inbox.
